Oncology
Cancer treatment in China
Why patients travel, what it costs, where the national centres are, and an honest account of when travelling is the wrong call.
Cancer patients from the United States and Canada travel to China mainly for CAR-T cell therapy and for treatment they cannot access quickly at home. CAR-T in China is widely reported at roughly $150,000–230,000 against $550,000–850,000 in the US. Treatment is generally schedulable within weeks of an accepted case.
Why patients come
Cost, at a scale that changes decisions
In oncology the gap between Chinese and US pricing is wider than in any other field. For cell therapy it is the difference between a treatment being available to a family and not.
Time, when time is the clinical variable
Waiting on prior authorisation, or on a place in a domestic queue, has a cost that is measured in disease progression rather than in money. Once a hospital has accepted a case, treatment is generally schedulable within weeks.
Access to therapies approved earlier
China has approved more CAR-T products than any other country, and several reached routine clinical use there ahead of North America.
CAR-T cell therapy
CAR-T is a personalised cell therapy for certain blood cancers, chiefly some lymphomas, leukaemias and myeloma. Your own T-cells are collected, re-engineered to recognise the cancer, and returned to you. It is demanding treatment with real toxicity, delivered at specialist centres, and it is the single biggest reason patients from North America now travel to China for cancer care.
| Where | Indicative cost | Time in country |
|---|---|---|
| China | $150,000 – $230,000 | 6–10 weeks in country |
| United States | $550,000 – $850,000 | — |
Not every cancer is a CAR-T cancer, and not every patient with a qualifying diagnosis is a candidate. Eligibility turns on the specific disease, what treatment you have already had, and whether you are well enough for the therapy. That assessment is made by the treating centre from your records, not by us.
For other procedures and what a trip costs beyond the hospital invoice, see what treatment in China costs.
Other cancer care we coordinate
Surgical oncology
Resection and reconstruction at high-volume teaching hospitals.
Systemic therapy
Chemotherapy, targeted agents and immunotherapy.
Radiotherapy
Including proton and heavy-ion facilities at selected centres.
Second opinions
A multidisciplinary review of your records without travelling first.
A remote second opinion is often the right first step. It costs a fraction of a trip, and it sometimes concludes that your current plan at home is the right one.
Where oncology sits
China’s national hospital ranking identifies dedicated cancer centres separately from general hospitals. Among the cities we coordinate in:
- Beijing — a national oncology centre, and 21 of China’s top 100 hospitals overall.
- Shanghai — a national oncology centre, and 18 of China’s top 100 hospitals overall.
- Guangzhou — a national oncology centre, and 10 of China’s top 100 hospitals overall.
What we need from you
Oncology cases are assessed from source documents. The pathology report and recent imaging in DICOM format matter more than anything you can write in a form — a centre asked to assess a cancer case from a summary will decline or hedge. Our records guide sets out exactly what to request and how.
When travelling is the wrong call
Sometimes it is. If you are too unwell to fly safely, if your treatment is time-critical and the logistics would delay it, if the same therapy is available to you at home on a workable timeline, or if your case is not one a partner centre would accept — we will tell you, and we will say why.
Nothing on this page is medical advice, and no page can tell you whether a treatment is right for you. That is a conversation with an oncologist who has read your records.
Sources
Send us the pathology report
A case manager reads every submission and replies within 24 hours — including when the answer is that you should be treated at home.
Request a free case review